The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

BTOG 2020 | ADSCaN trial: testing accelerated radiotherapy in NSCLC

Name: ADSCaN trial: testing accelerated radiotherapy in NSCLC
Uploaded: 2020-01-30T00:00:00Z
Duration: 59 s
Description: Matthew Hatton, MSc, MBChB, MRCP, FRCP, FRCR, University of Sheffield, Sheffield, UK, discusses the aims of the ADSCaN trial (ISRCTN47674500) testing accelerated, dose-escalated, chemo-radiotherapy in NSCLC. This interview took place at the 18th British Thoracic Oncology Group (BTOG) 2020 congress held in Dublin, UK.

Matthew Hatton • 30 Jan 2020

BTOG 2020

Lung Cancer Non-Small Cell Lung Cancer

Matthew Hatton, MSc, MBChB, MRCP, FRCP, FRCR, University of Sheffield, Sheffield, UK, discusses the aims of the ADSCaN trial (ISRCTN47674500) testing accelerated, dose-escalated, chemo-radiotherapy in NSCLC. This interview took place at the 18th British Thoracic Oncology Group (BTOG) 2020 congress held in Dublin, UK.